Core Insights - Immuneering Corporation is focused on developing Deep Cyclic Inhibitors, specifically atebimetinib, to improve overall survival in cancer patients by shrinking tumors durably and minimizing resistance [1][4] - The company will present findings at the AACR Annual Meeting, highlighting atebimetinib's ability to mitigate resistance mechanisms in RAS-mutant tumors [2][3] Company Overview - Immuneering is a late-stage clinical oncology company dedicated to enhancing the quality of life and survival rates for cancer patients [4] - The lead product candidate, atebimetinib, is an oral, once-daily medication targeting MEK, aimed at treating various cancer types, including pancreatic cancer [4] - The company plans to initiate a pivotal Phase 3 trial, MAPKeeper 301, in mid-2026, evaluating atebimetinib in combination with chemotherapy for first-line pancreatic cancer patients [4] Research Presentation Details - The poster presentation titled "Atebimetinib's Deep Cyclic Inhibition of MEK Constrains MAPK-Axis Adaptive and Acquired Alterations in Patients with RAS-Mutant Tumors" will take place on April 20, 2026, from 9:00 AM to 12:00 PM ET [3] - The analysis will include data from at least 64 patients with RAS-mutant solid tumors, demonstrating the potential of Deep Cyclic Inhibitors to provide sustained clinical benefits [2][3]

Core Viewpoint - Analyst sentiment has turned positive for X4 Pharmaceuticals, Immuneering, and Tango Therapeutics, with new or maintained Buy ratings ahead of pivotal clinical trial readouts in 2026 [1] Group 1: Company Summaries - **X4 Pharmaceuticals (XFOR)**: Received a Buy rating from Guggenheim with a price target of $12, indicating significant upside from the current trading price of $3.97. The company raised $240.3 million, extending its cash runway to the end of 2028, and is focused on mavorixafor, a potential first-in-class oral CXCR4 antagonist [1] - **Immuneering (IMRX)**: Maintained an Overweight rating from Piper Sandler with a revised price target of $12, down from $13. The company is on track for key clinical catalysts, including updated ctDNA data and Phase 2a survival data in pancreatic cancer expected in 2026 [1] - **Tango Therapeutics (TNGX)**: Stifel raised its price target to $24 from $15 while maintaining a Buy rating. The company has seen a significant stock increase of 87.25% year-to-date and is preparing for a pivotal study in pancreatic cancer [1] Group 2: Market Performance and Analyst Ratings - All three companies have received Buy or Overweight ratings from analysts, with substantial gaps between current trading prices and analyst targets, reflecting the binary nature of clinical-stage biotech [1] - X4 Pharmaceuticals has a consensus target of $9.33, more than double its current share price, while Immuneering has gained 257.24% over the past year but is down 17.48% year-to-date [1] - Tango Therapeutics is trading close to its 52-week high, indicating that much of the near-term re-rating has already occurred, with 10 of 11 analysts rating it a Buy or Strong Buy [1]

Core Insights - Immuneering Corporation reported a 64% overall survival rate at 12 months for first-line pancreatic cancer patients treated with atebimetinib + mGnP, significantly higher than the standard of care benchmark of 35% [1][2][3] - The company is on track to initiate the pivotal Phase 3 MAPKeeper 301 trial in mid-2026, following alignment with the FDA and EMA on trial design [1][3] - Immuneering ended 2025 with $217 million in cash and equivalents, providing a financial runway into 2029 [1][5] Clinical Developments - The ongoing Phase 2a trial of atebimetinib + mGnP showed a median follow-up of 13.4 months with a favorable safety profile, where only neutropenia and anemia were observed at grade 3 or higher in over 10% of patients [3] - The company plans to begin dosing in a Phase 2 trial of atebimetinib + Libtayo for first-line RAS-mutant non-small cell lung cancer in the second half of 2026 [1][3] Financial Performance - For Q4 2025, research and development expenses were $9.3 million, down from $14.9 million in Q4 2024, while full-year R&D expenses decreased to $42 million from $48 million [8] - General and administrative expenses for Q4 2025 increased to $4.5 million from $3.7 million in Q4 2024, with full-year G&A expenses rising to $17.3 million from $16.1 million [8] - The net loss for Q4 2025 was $11.6 million, or $0.18 per share, compared to a net loss of $18.1 million, or $0.58 per share, in Q4 2024 [8] Strategic Positioning - Immuneering's lead product candidate, atebimetinib, is a Deep Cyclic Inhibitor targeting MEK, designed to improve survival across various cancer types, particularly those driven by the MAPK pathway [6][9] - The company has a solid pipeline and is well-positioned to advance its mission of improving patient outcomes in oncology [2][9]

Core Viewpoint - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments aimed at improving patient survival and quality of life [2] Company Overview - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, which aim to enhance overall survival through three mechanisms: durable tumor shrinkage with reduced resistance, counteracting cachexia to preserve body mass, and minimizing side effects to improve performance status and combinability [2] - The lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, targeting various cancer indications, particularly MAPK pathway-driven tumors like pancreatic cancer [2] - The company plans to initiate dosing for the MAPKeeper 301 trial in mid-2026, a pivotal Phase 3 study evaluating atebimetinib in combination with chemotherapy for first-line pancreatic cancer patients [2] Upcoming Events - Immuneering's management will present at the Leerink Global Healthcare Conference in Miami, Florida, from March 9-11, 2026, with CEO Ben Zeskind discussing the company's pipeline, platform, and business strategy [1]

Summary of Immuneering's Conference Call Company Overview - **Company**: Immuneering - **Focus**: Development of atebimetinib, a novel oral drug candidate aimed at improving survival in first-line pancreatic cancer and other cancers Key Points Industry and Product - **Industry**: Biopharmaceuticals, specifically oncology - **Product**: Atebimetinib, categorized as a Deep Cyclic Inhibitor, designed to improve overall survival through three mechanisms: tumor shrinkage, body mass preservation, and side effect minimization [2][28] Clinical Data and Comparisons - **Survival Rates**: Reported 64% overall survival at 12 months in Phase 2a study, compared to a 35% benchmark for standard care (gemcitabine/nab-paclitaxel) [2][3][10] - **Disease Control Rate**: 81% in patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel, significantly higher than the 48% benchmark for standard care [6][17] - **Progression-Free Survival**: 8.5 months, compared to 5.5 months for standard care [16] - **Overall Response Rate**: 39%, higher than the 23% benchmark from standard care [16] Mechanisms of Action - **Three Mechanisms**: 1. **Tumor Shrinkage**: Effective in both RAS and RAF-driven tumors 2. **Body Mass Preservation**: 84% of patients maintained or gained weight, counteracting cachexia [6][8] 3. **Minimizing Side Effects**: Only two categories of Grade 3 or higher adverse events (neutropenia and anemia) seen in over 10% of patients [18][19] Future Studies and Trials - **Phase 3 Study**: MAPKeeper 301, a global randomized pivotal trial, will compare atebimetinib plus modified gemcitabine/nab-paclitaxel against standard care, with overall survival as the primary endpoint [3][27] - **Patient Enrollment**: Expanded cohort of over 50 patients expected to report data in the first half of 2026 [21][22] Regulatory and Market Position - **Regulatory Alignment**: Fully aligned with FDA and EMA for the Phase 3 study [3][29] - **Market Potential**: Targeting a broad range of RAS, RAF, and other MAPK-driven cancers, which account for about half of all tumors [4][30] Key Opinion Leader (KOL) Feedback - KOLs express excitement about the triple mechanism of action, emphasizing its potential to enhance patient quality of life and survival [33][36] Conclusion - Immuneering aims to establish atebimetinib as the new standard of care in first-line pancreatic cancer, leveraging its unique mechanisms to improve patient outcomes and quality of life [46][47]

Core Viewpoint - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments, particularly through its lead product candidate, atebimetinib, which targets various cancer indications [1][3]. Group 1: Company Overview - Immuneering Corporation is dedicated to keeping cancer patients alive and helping them thrive by developing a new category of cancer medicines known as Deep Cyclic Inhibitors [3]. - The lead product candidate, atebimetinib, is an oral, once-daily medication designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, including pancreatic cancer [3]. - A Phase 3 trial for atebimetinib in first-line pancreatic cancer is expected to begin dosing in mid-2026 [3]. Group 2: Upcoming Events - Management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, discussing the company's pipeline, platform, and business strategy [1]. - The presentation is scheduled for February 26, 2026, at 10:00 am ET and will be available via live webcast and archived on the company's Investor Relations website [2].

Market Performance - U.S. stocks showed mixed performance, with the Dow Jones index increasing by 0.54% to 49,261.60, while the NASDAQ fell by 0.62% to 23,437.73 and the S&P 500 dropped by 0.05% to 6,917.76 [1] - Industrial shares rose by 1.4% on Thursday, indicating strength in that sector [1] Sector Performance - Information technology stocks decreased by 1.4% on Thursday [2] Commodities - Oil prices increased by 1.8% to $56.98, while gold prices slightly decreased by 0.1% to $4,456.70. Silver fell by 3.6% to $74.820, and copper dropped by 1.7% to $5.7600 [6] European Market - European shares were mixed, with the eurozone's STOXX 600 declining by 0.27%, while Spain's IBEX 35 Index rose by 0.27%. London's FTSE 100 fell by 0.06%, Germany's DAX decreased by 0.08%, and France's CAC 40 increased by 0.06% [7] Asian Market - Asian markets closed lower, with Japan's Nikkei 225 down by 1.63%, Hong Kong's Hang Seng Index declining by 1.17%, China's Shanghai Composite slipping by 0.07%, and India's BSE Sensex falling by 0.92% [10] Company News - Flyexclusive Inc shares surged by 126% to $7.10 after being named an authorized Starlink Aviation dealer [9] - Enliven Therapeutics Inc shares increased by 54% to $23.81 following positive initial data from a clinical trial for chronic myeloid leukemia [9] - MoonLake Immunotherapeutics shares rose by 29% to $14.54 after receiving FDA feedback on its treatment for hidradenitis suppurativa [9] - Immuneering Corp shares dropped by 39% to $5.10 after announcing updated trial data for pancreatic cancer [9] - Acrivon Therapeutics Inc shares fell by 31% to $2.05 after releasing clinical data for endometrial cancer [9] - CorMedix Inc shares decreased by 23% to $8.00 following preliminary revenue results for Q4 and FY25 [9] Economic Indicators - U.S. initial jobless claims rose by 8,000 to 208,000, slightly below market expectations of 210,000 [3][12] - Nonfarm business sector labor productivity increased by 4.9% in Q3, following a revised 4.1% gain in the previous quarter [12] - Unit labor costs in the nonfarm business sector fell by 1.9% in Q3, contrasting with market expectations of a 1.0% increase [12] - The U.S. trade deficit narrowed to $29.4 billion in October, the smallest since June 2009, compared to a revised $48.1 billion in September [12]

Market Overview - U.S. stocks traded lower, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow decreased by 0.05% to 48,972.29, the NASDAQ declined by 0.57% to 23,448.86, and the S&P 500 fell by 0.14% to 6,911.57 [1] - Information technology stocks dipped by 1.4% on Thursday [2] - European shares were mostly lower, with the eurozone's STOXX 600 slipping 0.3% [7] - Asian markets closed lower, with Japan's Nikkei 225 falling 1.63% [9] Company Performance - Acuity Inc. (NYSE:AYI) reported fiscal first-quarter 2026 results, achieving a 20.2% year-over-year net sales growth to $1.14 billion, in line with analyst expectations. The adjusted EPS was $4.69, surpassing the consensus estimate of $4.59 [3] - Flyexclusive Inc. (NYSE:FLYX) shares surged 126% to $7.44 after being named an authorized Starlink Aviation dealer [8] - Enliven Therapeutics Inc. (NASDAQ:ELVN) shares increased by 59% to $24.55 following positive initial data from a Phase 1b clinical trial [8] - Nuvve Holding Corp. (NASDAQ:NVVE) shares rose by 46% to $5.11 after regaining Nasdaq compliance [8] - Immuneering Corp. (NASDAQ:IMRX) shares dropped 35% to $5.45 after announcing updated survival and safety data from a Phase 2a trial [8] - Acrivon Therapeutics Inc. (NASDAQ:ACRV) shares fell 29% to $2.10 after announcing clinical data related to endometrial cancer [8] - CorMedix Inc. (NASDAQ:CRMD) shares decreased by 25% to $8.33 following preliminary revenue results [8] Commodities - Oil prices increased by 1.9% to $57.03, while gold prices decreased by 0.6% to $4,436.20. Silver fell by 4.7% to $73.925, and copper dropped by 2.5% to $5.7120 [6]

Core Insights - U.S. stock futures are lower, with Dow futures dropping over 100 points on Thursday [1] - Immuneering Corp's shares fell 20.7% to $6.61 in pre-market trading following the announcement of updated survival and safety data from its Phase 2a trial for pancreatic cancer [1] Company Movements - Elme Communities shares decreased 82.8% to $2.98 in pre-market trading [3] - Erasca Inc shares fell 14% to $4.45 after a previous rise of 42% on Wednesday [3] - Phathom Pharmaceuticals Inc shares dropped 13.7% to $15.60 after announcing a $130 million public offering [3] - United Microelectronics Corp shares declined 6.3% to $8.37 after a 10% increase on Wednesday due to reported sales growth [3] - Canadian Solar Inc shares decreased 6.1% to $20.68 following a proposed $200 million public offering [3] - Trevi Therapeutics Inc shares fell 6.1% to $11.00 in pre-market trading [3] - Revolution Medicines Inc shares dipped 6% to $96.57 after reports that AbbVie is not in discussions with the company [3] - Sibanye Stillwater Ltd shares decreased 5.7% to $15.01 in pre-market trading [3] - Vanda Pharmaceuticals Inc shares fell 5% to $8.11 despite FDA approval of its product to prevent motion-induced vomiting [3] - Logitech International SA shares declined 4.8% to $94.91 ahead of its third quarter fiscal year 2026 financial results release [3]

Company Performance - AZZ Inc reported adjusted earnings of $1.52 per share, exceeding market estimates of $1.47 per share [1] - The company's sales reached $425.746 million, surpassing expectations of $418.164 million [1] - AZZ shares increased by 2.1% to $112.09 in pre-market trading following the earnings report [1] Notable Stock Movements - CIMG Inc gained 33.3% to $1.44 after securing approximately $124 million in commercial contracts [4] - ECD Automotive Design Inc rose 26.4% to $0.59 due to talks for strategic deals valued between $2 million and $10 million [4] - Acrivon Therapeutics Inc increased by 22.1% to $3.60, announcing a clinical update on its ongoing studies [4] - Nuvve Holding Corp gained 17.1% to $4.11 after a previous 60% rise [4] - RenovoRx Inc surged 16.8% to $1.18 in pre-market trading [4] - Serina Therapeutics Inc rose 16.4% to $2.82 after a 15% increase on Wednesday [4] - Super League Enterprise Inc increased by 11.2% to $0.68 following an asset purchase agreement [4] - Northrop Grumman Corp gained 6.8% to $616.26, influenced by a potential increase in the military budget [4] Declining Stocks - Immuneering Corp fell 20.7% to $6.61 after announcing updated trial data [4] - Erasca Inc decreased by 14% to $4.45 after a previous 42% rise [4] - Phathom Pharmaceuticals Inc dropped 13.7% to $15.60 following a $130 million public offering announcement [4] - United Microelectronics Corp fell 6.3% to $8.37 after a previous 10% increase [4]